Abraham Tara S, Snook Adam E
Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, 1020 Locust Street Philadelphia, PA 19107, USA.
Per Med. 2017 May;14(3):259-270. doi: 10.2217/pme-2016-0108. Epub 2017 May 5.
Cancer immunotherapy has long offered the promise of producing cancer treatments that are more effective and less toxic than traditional chemotherapy and radiotherapy. That potential has only begun to be realized in the last 5 years with the first US FDA-approved cancer vaccine (sipuleucel-T), checkpoint inhibitors and adoptive cell therapy. While these therapies have been remarkably more effective than previous cancer immunotherapeutics, they are often limited by their inherently personalized nature. Indeed, each patient's immune system and cancer are unique, limiting the scalability and generalizability of new approaches. However, emerging solutions may overcome these limitations, producing 'off-the-shelf' cancer immunotherapies that transform patient outcomes.
长期以来，癌症免疫疗法一直有望开发出比传统化疗和放疗更有效、毒性更小的癌症治疗方法。在过去5年里，随着首个获得美国食品药品监督管理局（FDA）批准的癌症疫苗（西妥昔单抗）、检查点抑制剂和过继性细胞疗法的出现，这一潜力才刚刚开始得以实现。虽然这些疗法比以往的癌症免疫疗法显著更有效，但它们往往受到其固有的个性化性质的限制。事实上，每个患者的免疫系统和癌症都是独特的，这限制了新方法的可扩展性和通用性。然而，新出现的解决方案可能会克服这些限制，产生改变患者治疗效果的“现成可用”的癌症免疫疗法。
